biote (BTMD) Competitors $4.21 +0.02 (+0.48%) Closing price 07/3/2025 03:46 PM EasternExtended Trading$4.21 0.00 (0.00%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, PRAX, ZYME, and LENZShould you be buying biote stock or one of its competitors? The main competitors of biote include Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Zymeworks LENZ Therapeutics Spyre Therapeutics (NASDAQ:SYRE) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends. Do insiders and institutionals have more ownership in SYRE or BTMD? 80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 6.2% of Spyre Therapeutics shares are held by company insiders. Comparatively, 24.0% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, SYRE or BTMD? Spyre Therapeutics has a beta of 2.68, suggesting that its stock price is 168% more volatile than the S&P 500. Comparatively, biote has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Does the media prefer SYRE or BTMD? In the previous week, Spyre Therapeutics had 1 more articles in the media than biote. MarketBeat recorded 2 mentions for Spyre Therapeutics and 1 mentions for biote. biote's average media sentiment score of 0.67 beat Spyre Therapeutics' score of 0.00 indicating that biote is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral biote 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend SYRE or BTMD? Spyre Therapeutics presently has a consensus price target of $53.40, suggesting a potential upside of 237.12%. biote has a consensus price target of $8.00, suggesting a potential upside of 90.02%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spyre Therapeutics is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25biote 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SYRE or BTMD more profitable? biote has a net margin of 10.93% compared to Spyre Therapeutics' net margin of 0.00%. biote's return on equity of -19.44% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Spyre TherapeuticsN/A -77.46% -41.06% biote 10.93%-19.44%20.12% Which has better earnings and valuation, SYRE or BTMD? biote has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpyre Therapeutics$890K1,072.85-$208.02M-$3.77-4.20biote$197.19M1.17$3.16M$0.616.90 Summarybiote beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.33M$10.41B$5.53B$9.02BDividend YieldN/A2.07%5.22%3.99%P/E Ratio6.9017.0327.7520.25Price / Sales1.1729.81438.76119.26Price / Cash5.5123.9726.2128.59Price / Book-1.513.668.025.65Net Income$3.16M$235.43M$3.18B$249.15M7 Day Performance4.73%1.53%2.88%2.91%1 Month Performance9.92%1.07%1.67%4.11%1 Year Performance-43.03%-10.17%34.26%20.98% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote3.0867 of 5 stars$4.21+0.5%$8.00+90.0%-43.0%$230.33M$197.19M6.90194SYRESpyre Therapeutics1.3437 of 5 stars$14.97-1.6%$53.40+256.7%-37.9%$917.39M$890K-3.9773MLYSMineralys Therapeutics2.1327 of 5 stars$13.53-1.3%$32.25+138.4%+16.9%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.4005 of 5 stars$8.85-3.8%$18.17+105.3%-39.6%$890M$169.12M-32.7870PHVSPharvaris1.7555 of 5 stars$17.60+3.5%$36.20+105.7%+12.7%$888.93MN/A-5.8530Positive NewsGap UpNRIXNurix Therapeutics1.6201 of 5 stars$11.39-2.1%$30.18+164.9%-34.6%$887.38M$54.55M-4.07300Trending NewsUpcoming EarningsARDXArdelyx4.4328 of 5 stars$3.92+6.2%$10.89+177.8%-18.8%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.2422 of 5 stars$10.15-1.6%$19.17+88.8%+40.1%$878.66MN/A-5.4380PRAXPraxis Precision Medicines2.9429 of 5 stars$42.05-2.2%$109.90+161.4%+17.2%$875.87M$8.55M-3.92110ZYMEZymeworks2.0771 of 5 stars$12.55+0.6%$21.00+67.3%+44.5%$873.19M$93.38M-8.37460LENZLENZ Therapeutics1.3332 of 5 stars$29.31-2.9%$46.60+59.0%+80.2%$849.45MN/A-16.56110 Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Ardelyx Alternatives Oric Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTMD Stock Alerts